|
gptkbp:instanceOf
|
benzodiazepine
sedative
|
|
gptkbp:ATCCode
|
gptkb:N05CD01
|
|
gptkbp:bioavailability
|
80% (oral)
|
|
gptkbp:brand
|
gptkb:Dalmane
|
|
gptkbp:CASNumber
|
gptkb:17617-23-1
|
|
gptkbp:category
|
benzodiazepine
GABA-A receptor positive allosteric modulator
long-acting benzodiazepine
sedative-hypnotic
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Roche
|
|
gptkbp:eliminationHalfLife
|
40-250 hours (active metabolite)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
gptkb:C21H23ClFN3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
flurazepam
|
|
gptkbp:introducedIn
|
1970
|
|
gptkbp:IUPACName
|
gptkb:7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptor
|
|
gptkbp:meltingPoint
|
86-87°C
|
|
gptkbp:metabolism
|
gptkb:N-desalkylflurazepam
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
96.5%
|
|
gptkbp:PubChem_CID
|
3277
3393
CHEMBL1200472
DB00690
|
|
gptkbp:riskFactor
|
tolerance
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
anterograde amnesia
drowsiness
|
|
gptkbp:synonym
|
gptkb:Dalmadorm
gptkb:Dormalin
gptkb:flurazepam_hydrochloride
|
|
gptkbp:UNII
|
2ZK1V6YX04
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|